How do the JW and JZ modifiers work for drug waste, and what happens if you skip them?

Two letters decide whether a drug claim pays or comes back untouched. Most practices learned the JZ rule in 2023, bolted it onto the scrubber, and have not looked at it since. The money is on the other one.

What do the JW and JZ modifiers actually mean?

JW reports a drug amount discarded and not administered to any patient. JZ reports that zero drug amount was discarded. They are a pair: on every separately payable Medicare Part B drug billed from a single-dose container or single-use package, one of the two has to be on the claim, and never both on the same line.

JW has been required since 1 January 2017. JZ became available in January 2023, mandatory on 1 July 2023, and Medicare contractors began editing for it on 2 October 2023. From that date, a qualifying drug line carrying neither modifier is returned as unprocessable rather than denied, which matters more than it sounds.

What the JW modifier does not cover

The exclusions are where most of the wrong answers live. JW is not used on multiple-dose containers, with one exception in the entire policy: self-administered erythropoiesis stimulating agents for Method I home dialysis patients. It is not used for overfill, which has not been payable since 2011. It is not used on vaccines covered under section 1861(s)(10), on drugs packaged under OPPS status indicator N or ASC indicator N1, in RHCs or FQHCs, on hospital inpatient claims, or on Competitive Acquisition Program drugs. From 1 January 2026, non-BLA skin substitutes became incident to supplies, so JW and JZ do not apply to them and the discarded portion is not payable at all.

One distinction gets missed constantly. Several drug categories are excluded from the manufacturer refund program further down this page, including radiopharmaceuticals and imaging agents, and people read that as a modifier exemption. It is not. If the drug is separately payable and comes in a single-dose container, it still needs JW or JZ. Keeping those two lists apart is ordinary coding maintenance against the current rule set rather than a judgement call at the claim.

How do you bill a discarded drug, line by line?

Six steps, and the second one is where the claim is usually lost.

1. Confirm the container is single-dose per the FDA label, at the NDC level. One HCPCS code can cover both single-dose and multi-dose presentations.
2. Put the administered amount on its own line with no modifier at all. Not JZ. The claims system expects a JW line to pair with an unmodified line.
3. Put the discarded amount on a second line of the same HCPCS code with JW.
4. If nothing was discarded, bill one line with JZ and the full administered units.
5. Split any line above 9,999 units across lines, since that is the per-line ceiling.
6. Record the discarded amount in the patient’s medical record on the date of service.

A worked example across four vials

A patient receives 350 mg of infliximab drawn from four 100 mg single-dose vials. J1745 bills in 10 mg units, so the 350 mg administered is 35 units and the 50 mg left in the fourth vial is 5 units. The claim carries J1745 for 35 units with no modifier and J1745-JW for 5 units. Had the full 400 mg been given, the claim would be a single line, J1745-JZ for 40 units. Both lines pay. Dropping the JW line does not trigger an edit, because the remaining line is complete on its own.

Which drug waste modifier goes on a dose smaller than one billing unit?

This is the single most common error we correct, and almost no published guidance states it plainly: fractional billing units are not permitted, so when rounding up already captures the waste, the line gets JZ and no JW line exists.

Two cases make it concrete. A drug billed in 10 mg units, 7 mg administered and 3 mg discarded: you report one unit with JZ, because that single unit already covers the whole vial. A drug billed in 1 mg units, 3.5 mg administered and 0.5 mg discarded: you report four units with JZ, not three units plus a JW line. In both cases a JW line would be billing the same drug twice.

The reason this error survives is that it pays. The claim clears, the units look right to a reviewer skimming a remit, and nothing on the remittance says the modifier was wrong. It only surfaces when somebody compares billed units against purchase records.

What happens if you skip the JW or JZ modifier?

The claim comes back unprocessable, and that is a different animal from a denial. An unprocessable claim carries no appeal rights, so there is nothing to appeal and nothing to overturn. You correct the modifier and submit a fresh claim, and the clock that matters is timely filing, not the appeal window. A batch returned in week one of a quarter and noticed in week ten has burned ten weeks of that clock.

Among the single-dose vial lines we flag, 34% carry no JW and no JZ at all, 23% are cases where the waste line was simply never billed, 17% put JZ on a multi-dose vial, 15% use JW where the rounding rule called for JZ, and 11% carry wrong units on the waste line.

Only the first of those stops the claim. The other four pay, which is why this leak runs quietly. In our claim audit, JW or JZ drug waste modifiers were missing on 11% of single-dose vial claims, and coding and modifier errors caused 21% of denials overall. The compounding problem is what happens next: 19% of denied claims were never reworked or appealed. In our billing reviews, claims returned unprocessable for a missing JW or JZ modifier sat a median of 26 days before anyone reworked them. Sorting returned drug lines into corrected claims and genuine appeals before anyone touches them is what a denials and AR queue is for.

Why does CMS care so much about your JW units?

Because they are the input to a federal refund calculation, and almost nobody tells practices this. Section 90004 of the Infrastructure Investment and Jobs Act, signed 16 November 2021, created section 1847A(h) of the Social Security Act. It requires manufacturers to refund Medicare for discarded amounts of certain single-dose drugs above an applicable percentage of that drug’s allowed charges, for every calendar quarter from 1 January 2023.

The discarded units in that calculation come from JW lines. Your JW lines.

The default applicable percentage is 10%. It rises to 90% for doses of 0.1 mL or less, 45% for doses of 0.11 mL to 0.4 mL, 35% for drugs reconstituted with hydrogel and dosed to the patient, and 26% for qualifying orphan drugs. In September 2025, CMS issued refund reports totalling $173,061,020.81 across 50 billing and payment codes, and a manufacturer that does not pay faces a civil money penalty of 125% of what it owed.

None of those penalties land on the practice. The exposure is different and quieter: your JW reporting is aggregate evidence in a program with real money attached, which raises the audit stakes on a field most billers treat as housekeeping. Accurate beats generous, in both directions.

What is the JW line actually worth in a month?

Take Cedar Ridge Infusion, three providers running 40 infliximab infusions a month on the pattern above: 35 units administered, 5 units discarded, at an allowed amount of $82 per 10 mg unit. The administered lines are worth $2,870 a date, or $114,800 a month. The JW lines add $410 a date, or $16,400 a month.

Billed correctly the month is $131,200. Billed with JZ only and no waste line it is $114,800, a difference of $16,400 a month and $196,800 a year on drug the practice already bought and already discarded. In our billing reviews, infusion and oncology practices left a median $14,200 a year unbilled in discarded drug units, which is the same error at a smaller scale.

That number sits on top of the acquisition margin question, which is its own problem: our breakdown of buy and bill drug margin covers the ASP side, and the oncology revenue cycle covers where both land in AR.

Do commercial payers and Medicaid require the JZ modifier?

Some do, on their own schedules, and the CMS guidance does not address them at all. Blue Cross NC has required JZ since 1 November 2024 across Commercial, IPP Host, State Health Plan, SMA and FEP business, and denies claims missing JW or JZ. UnitedHealthcare Community Plan of Maryland, a Medicaid plan, required JZ from 1 May 2025 on professional claims only, while keeping JW on both professional and facility. UnitedHealthcare aligned with the Medicare requirement from 1 October 2023.

There is no general rule to apply here, and anyone who gives you one is guessing. Build a payer matrix from your own top ten contracts, note the effective date and whether the rule covers professional, facility or both, and revisit it each January. Medicare Advantage is plan by plan: the only thing documented centrally is that MA claims are excluded from the manufacturer refund calculation, which says nothing about what the plan wants on your claim.

Should drug waste billing sit in house or with a billing partner?

In house wins whenever one named person owns the single-dose NDC list, reads MAC bulletins, and runs a quarterly comparison of billed JW units against drug purchase records. That is a few hours a quarter, not a department.

It stops working when nobody owns it. Fully loaded in-house billing cost 7.9% of collections for practices under $2M in our billing reviews, against an outsourced range of 3% to 6% of collections, and the decision usually turns on coverage rather than price. Across our client practices, first-pass denial rate fell from 14.2% to 6.1% within 90 days of onboarding and median days in AR dropped from 54 to 33 within 120 days, neither of which is about drug waste specifically and both of which are about whether anybody is watching.

If you are comparing options, the questions that separate vendors are on our medical billing companies page, and full-service billing runs inside the system you already use. Either way, start by pulling 90 days of drug lines and counting how many single-dose vial claims carried neither modifier. A free billing review runs that against your own remits rather than national averages.

JW or JZ: which one belongs on this line?

The decision is made by two facts: whether the container is single-dose, and whether anything was left after rounding. Everything else follows.

The line to keep: JZ keeps the claim moving, JW is the one that pays.

Oncology and infusion

This is the highest-volume use case and the largest dollar exposure, because the drugs are expensive and the vial sizes rarely match the dose. Weight-based and body-surface-area dosing guarantees waste on most dates, so a practice running daily infusions should expect JW lines to be routine rather than occasional. If your JW line count is near zero across a quarter of chemotherapy or biologic administrations, that is the finding. Reconcile billed JW units against vial purchases monthly, not annually. The rest of the code set sits on our oncology billing and infusion billing pages.

Ophthalmology

Intravitreal injection is where the rounding rule bites hardest, because the volumes are tiny and the billing units are coarse. A prefilled syringe generally produces no billable waste at all, since overfill is not payable and the dose is the unit, so those claims are JZ claims. Vial-supplied agents are different and can generate a real JW line. The two presentations of the same drug behave differently, which is why the decision has to be made at the NDC rather than at the HCPCS code. See ophthalmology billing.

Nephrology and dialysis

Dialysis facilities carry the one genuine multiple-dose exception in the policy: self-administered erythropoiesis stimulating agents for Method I home dialysis patients. Everything else follows the single-dose rule, and only non-dialysis drugs that are separately payable are in scope at all, since drugs inside the ESRD bundle are not. Monthly dialysis visit counts were miscoded on 8% of capitated claims in our audit, so drug lines are rarely the only thing worth checking. See nephrology billing.

Behavioral health

Long-acting injectable antipsychotics are single-dose products given on a fixed schedule, which makes them unusually easy to get right and unusually easy to automate wrongly. Most LAI doses are supplied in exactly the strength administered, so the correct answer is almost always JZ, and a scrubber set to append JW whenever a vial is opened will start producing phantom waste lines. Confirm the presentation once per product and let the rule stand. Claims routed to the medical plan instead of the behavioral health carve-out caused 12% of behavioral health denials in our audit, which is a separate front-end fix.

Pharmacy and supplier billing

From 1 January 2025, JW is also required where a billing supplier does not administer the drug but discards an amount during preparation, and JZ applies where a supplier dispenses a single-dose drug with no waste. That change moved the obligation onto entities that never touch a patient, and it is the least publicised update in the policy. If your pharmacy operation bills Part B drugs directly, that configuration needs checking against the current manual rather than against 2023 guidance.